Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Intelgenx Technologies's Business Segments
Intelgenx Technologies's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
-
Largest Segment
-
Total Revenue
$ 0
Regions Reported
1
Intelgenx Technologies does not report a distinct business-segment axis in its filings - its disaggregated revenue is disclosed by product and service category instead. See the Product & Service breakdown below.
Revenue Share by Region - FY
- Europe64.4%
Revenue by Geographic Region - FY
| Region | Revenue (Millions) | % of Total |
|---|---|---|
| Europe | $ 0 | 64.4% |
Revenue by Product & Service Category - FY
- Research and Development97.1%
- Royalties on Product Sales2.9%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Research and Development | $ 0 | 97.1% |
| Royalties on Product Sales | $ 0 | 2.9% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Intelgenx Technologies
Intelgenx Technologies Corp is a pharmaceutical company that specializes in the development and manufacturing of innovative drug delivery solutions. The company is based in Canada and was founded in 2003. It is publicly traded on the Toronto Stock Exchange under the ticker symbol IGX and on the OTCQB under the ticker symbol IGXTF.
Intelgenx focuses on utilizing its proprietary drug delivery technologies to improve the efficacy, safety, and convenience of existing drugs. Their primary technology platform is VersaFilm, which is a thin film drug delivery system that can be applied to various dosage forms, including oral strips, buccal films, and transdermal patches. This technology allows for precise and controlled release of active pharmaceutical ingredients.
The company collaborates with pharmaceutical partners to develop and commercialize innovative products using its drug delivery technologies. These partnerships typically involve licensing agreements, joint development projects, or research collaborations. Intelgenx has established collaborations with both generic and branded pharmaceutical companies, expanding its potential market reach.
In addition to the VersaFilm technology, Intelgenx also offers other drug delivery platforms, such as AdVersa, an abuse-deterrent technology that helps prevent misuse and abuse of opioids. This platform aims to address the growing concerns surrounding opioid addiction and overdose by creating formulations with built-in safety features.
Intelgenx's portfolio includes both generic and branded products. They have developed and commercialized several products, such as Rizaport, a formulation of rizatriptan for the treatment of migraines, and Montelukast VersaFilm, a generic version of the popular asthma medication. The company continuously evaluates new product opportunities and actively pursues regulatory approvals to expand its product offering.
The company also invests in research and development to enhance its drug delivery technologies and develop new formulations. They have a dedicated team of scientists and engineers who work on product development, formulation optimization, and process improvement. Intelgenx's R&D efforts are focused on addressing unmet medical needs and improving patient outcomes.
Intelgenx operates a state-of-the-art GMP-compliant manufacturing facility in Quebec, Canada. This facility is equipped with cutting-edge equipment and adheres to strict quality standards to ensure the production of high-quality pharmaceutical products. The company also has a strong intellectual property portfolio, including numerous patents and patent applications related to its drug delivery technologies.
Overall, Intelgenx Technologies Corp is a pharmaceutical company that specializes in developing and manufacturing innovative drug delivery solutions. With its proprietary technologies and collaborative approach, the company aims to improve the effectiveness, safety, and convenience of medications for patients worldwide.
Intelgenx focuses on utilizing its proprietary drug delivery technologies to improve the efficacy, safety, and convenience of existing drugs. Their primary technology platform is VersaFilm, which is a thin film drug delivery system that can be applied to various dosage forms, including oral strips, buccal films, and transdermal patches. This technology allows for precise and controlled release of active pharmaceutical ingredients.
The company collaborates with pharmaceutical partners to develop and commercialize innovative products using its drug delivery technologies. These partnerships typically involve licensing agreements, joint development projects, or research collaborations. Intelgenx has established collaborations with both generic and branded pharmaceutical companies, expanding its potential market reach.
In addition to the VersaFilm technology, Intelgenx also offers other drug delivery platforms, such as AdVersa, an abuse-deterrent technology that helps prevent misuse and abuse of opioids. This platform aims to address the growing concerns surrounding opioid addiction and overdose by creating formulations with built-in safety features.
Intelgenx's portfolio includes both generic and branded products. They have developed and commercialized several products, such as Rizaport, a formulation of rizatriptan for the treatment of migraines, and Montelukast VersaFilm, a generic version of the popular asthma medication. The company continuously evaluates new product opportunities and actively pursues regulatory approvals to expand its product offering.
The company also invests in research and development to enhance its drug delivery technologies and develop new formulations. They have a dedicated team of scientists and engineers who work on product development, formulation optimization, and process improvement. Intelgenx's R&D efforts are focused on addressing unmet medical needs and improving patient outcomes.
Intelgenx operates a state-of-the-art GMP-compliant manufacturing facility in Quebec, Canada. This facility is equipped with cutting-edge equipment and adheres to strict quality standards to ensure the production of high-quality pharmaceutical products. The company also has a strong intellectual property portfolio, including numerous patents and patent applications related to its drug delivery technologies.
Overall, Intelgenx Technologies Corp is a pharmaceutical company that specializes in developing and manufacturing innovative drug delivery solutions. With its proprietary technologies and collaborative approach, the company aims to improve the effectiveness, safety, and convenience of medications for patients worldwide.
Intelgenx Technologies Corp is a pharmaceutical company that specializes in the development of novel drug delivery systems and formulations. The company focuses particularly on the research and development of oral drug delivery technologies designed for a range of applications, including allowing for the improved bioavailability of drugs and enhancing patient compliance.
Segments
1. Pharmaceutical Development: Intelgenx operates primarily in the pharmaceutical sector, providing advanced drug formulation technologies. This segment emphasizes creating innovative drug delivery methods, leveraging unique platforms to enhance the effectiveness and usability of medications.
2. Partnerships and Collaborations: The company engages in strategic partnerships with other biotechnology and pharmaceutical companies. These collaborations typically focus on developing and commercializing new drug delivery systems, expanding their reach and expertise in various therapeutic areas.
3. Research and Development: Intelgenx invests significantly in R&D to explore new drug delivery technologies and improve existing formulations. This segment emphasizes innovation and aims to create medically beneficial products aimed at specific health conditions.
Products
Intelgenxs product offerings primarily revolve around their proprietary drug delivery systems. These include:
1. Vividrin®: An oral film formulation designed for the effective delivery of active pharmaceutical ingredients (API) via the oral cavity, providing rapid onset of action.
2. Intellitab™: A patented platform for oral delivery systems that allows for controlled release properties, enhancing bioavailability and patient compliance.
3. Oral Thin Film Products: These include products designed to dissolve quickly in the mouth, providing convenience and improved delivery for active ingredients that may otherwise be poorly absorbed in the gastrointestinal tract.
4. Montelukast for Allergies: A formulation designed for treating allergic rhinitis through a novel delivery method that offers ease of use and improved patient adherence compared to traditional formats.
Services
Intelgenx also offers a range of services, focusing on their expertise in drug formulation and development:
1. Formulation Development Services: The company provides services ranging from initial formulation development to clinical trial support. This includes assistance with dosage form design, stability testing, and scaling up for commercial production.
2. Contract Manufacturing: Intelgenx may offer contract manufacturing services that allow pharmaceutical companies to utilize their advanced technologies for their products. This includes producing the novel drug delivery systems they have developed.
3. Regulatory Support Services: The company navigates the complex regulatory landscape of drug approval processes, offering expertise to partners in compiling necessary documentation and submissions to gain regulatory approval from government agencies.
4. Consultation and Technical Services: Intelgenx provides consultation services to other pharmaceutical companies focused on improving product efficacy and compliance through innovative delivery systems. This includes technical support in the areas of formulation, stability, and delivery methods.
Through these segments, products, and services, Intelgenx Technologies Corp aims to facilitate the development of effective medication delivery systems that cater to the evolving needs of the healthcare sector, ultimately enhancing patient outcomes and satisfaction.
Segments
1. Pharmaceutical Development: Intelgenx operates primarily in the pharmaceutical sector, providing advanced drug formulation technologies. This segment emphasizes creating innovative drug delivery methods, leveraging unique platforms to enhance the effectiveness and usability of medications.
2. Partnerships and Collaborations: The company engages in strategic partnerships with other biotechnology and pharmaceutical companies. These collaborations typically focus on developing and commercializing new drug delivery systems, expanding their reach and expertise in various therapeutic areas.
3. Research and Development: Intelgenx invests significantly in R&D to explore new drug delivery technologies and improve existing formulations. This segment emphasizes innovation and aims to create medically beneficial products aimed at specific health conditions.
Products
Intelgenxs product offerings primarily revolve around their proprietary drug delivery systems. These include:
1. Vividrin®: An oral film formulation designed for the effective delivery of active pharmaceutical ingredients (API) via the oral cavity, providing rapid onset of action.
2. Intellitab™: A patented platform for oral delivery systems that allows for controlled release properties, enhancing bioavailability and patient compliance.
3. Oral Thin Film Products: These include products designed to dissolve quickly in the mouth, providing convenience and improved delivery for active ingredients that may otherwise be poorly absorbed in the gastrointestinal tract.
4. Montelukast for Allergies: A formulation designed for treating allergic rhinitis through a novel delivery method that offers ease of use and improved patient adherence compared to traditional formats.
Services
Intelgenx also offers a range of services, focusing on their expertise in drug formulation and development:
1. Formulation Development Services: The company provides services ranging from initial formulation development to clinical trial support. This includes assistance with dosage form design, stability testing, and scaling up for commercial production.
2. Contract Manufacturing: Intelgenx may offer contract manufacturing services that allow pharmaceutical companies to utilize their advanced technologies for their products. This includes producing the novel drug delivery systems they have developed.
3. Regulatory Support Services: The company navigates the complex regulatory landscape of drug approval processes, offering expertise to partners in compiling necessary documentation and submissions to gain regulatory approval from government agencies.
4. Consultation and Technical Services: Intelgenx provides consultation services to other pharmaceutical companies focused on improving product efficacy and compliance through innovative delivery systems. This includes technical support in the areas of formulation, stability, and delivery methods.
Through these segments, products, and services, Intelgenx Technologies Corp aims to facilitate the development of effective medication delivery systems that cater to the evolving needs of the healthcare sector, ultimately enhancing patient outcomes and satisfaction.